Sign in
SuspendedNo phase

Watch and Wait Management on Rectal Cancer Patients Using New Swift Local Therapy

Key facts

Who runs it
Sir Mortimer B. Davis - Jewish General Hospital
Where
Canada1 site in 1 countryChoose a country to see its sites
Trial code
Status
Suspended
People taking part
45 people, planned
Started
27 Oct 2020
Expected to end
Jan 2028
Type of study
Interventional
Treatments tested
  • External beam radiotherapy + Endorectal brachytherapy
Record updated
24 April 2026
Why it stopped
Issues with applicator

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Patients with histologic diagnosis by proctoscopic biopsy of invasive rectal adenocarcinoma will be considered for entry in this study
  • Patient in whom the diagnosis of invasive rectal cancer has been obtained by incisional biopsy (surgical or endoscopic biopsy) that the majority of the tumor has not been removed
  • The tumor should be either palpable by clinical rectal exam or accessible via a rigid proctoscope, and its proximal border should be located no more than 15 cm from the anal verge
  • Rectal cancer clinically stage as T2-T3 N1+ by MRI or endoscopic ultrasound
  • Tumor of 5 cm or less length, non obstructive
  • Patient is not suitable for surgery nor chemotherapy due to medical conditions
  • Patient must consent to be in the study and consent form must be signed, witnessed and dated prior to registration
  • Patients must be accessible geographically for follow up
  • Adults older than 18 years of age

Who cannot take part

  • Patient who demonstrate prior to randomization, evidence of free perforation, as manifested by free fluid in the abdomen
  • Patient who are curable by standard of care with either surgery or eligible for the Morpheus study
  • Patient who have received any previous therapy (radiation , chemotherapy) for rectal cancer
  • Patient whose tumor is fixed by clinical examination to surrounding structures, precluding the possibility of adequate surgical resection even with pelvic exenteration
  • Patient with malignant rectal tumors other than adenocarcinoma, i.e, sarcoma, lymphoma, carcinoid, squamous cell, cloacogenic, etc
  • Patient with psychiatric or addictive disorders that would preclude obtaining informed consent
  • Patient who have multiple primary tumors involving both the colon and rectum that would preclude them from being classified as having only rectal cancer
  • Patient with a performance status of 3 or 4
  • Patient with tumor involving the anal canal
  • Patient who are pregnant at the time of randomization

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Within our institution, the principal investigator have acquired expertise in endorectal brachytherapy, a localized treatment for colorectal cancer. Until now a modality which uses an endorectal applicator has been used, which has certain limitations. In the context of this study, a new applicator will be used which is already approved by Health Canada for endorectal brachytherapy, thereby improving the participant's quality of life and optimizing treatment time.

The group in the trial

  • External beam radiotherapy + Endorectal brachytherapyOther group

    In this study, all participants will receive a treatment of external beam radiotherapy without chemotherapy, which will be followed by three (3) treatments of endorectal brachytherapy with the new applicator.

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Pilot Study of Dose-escalation Strategy of Radiotherapy Followed by Endorectal Brachytherapy With the Use of a New Rectal Applicator in Inoperable, Ederly Rectal Cancer Patients
Record updated
24 April 2026